Posters

1

A CONSECUTIVE TREATMENT REGIMEN OF CLOBETASOL PROPIONATE 0.05% SPRAY FOLLOWED BY CALCITRIOL 3MCG/G OINTMENT FOR THE MANAGEMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS :

2

A VALIDATED HAND GRADING SCALE :

3

A VALIDATED LIP FULLNESS RATING SCALE :

4

A VALIDATED RATING SCALE FOR CROW’S FEET :

5

A VALIDATED RATING SCALE FOR MARIONETTE LINES :

6

AN EVALUATION OF THE COSMETIC APPEARANCE OF METRONIDAZOLE GEL, 1% WITH DAILY APPLICATION OF FACIAL COSMETICS :

7

DEVELOPMENT AND ASSESSMENT OF ONION EXTRACT CREAM WITH SUN PROTECTION FACTOR FOR THE IMPROVEMENT OF THE APPEARANCE OF POST SURGICAL SCARS :

8

EFFICACY OF DOXYCYCLINE MONOHYDRATE DELAYED-RELEASE CAPSULES, 40 MG IS EVIDENT REGARDLESS OF THE NUMBER OF INFLAMMATORY LESIONS AT BASELINE: A META-ANALYSIS FROM PHASE 3 STUDIES :

9

EFFICACY AND SAFETY OF ADAPALENE 0.1%/BENZOYL PEROXIDE 2.5% GEL IN REDUCING ANTIBIOTIC SENSITIVE AND RESISTANT STRAINS OF PROPIONIBACTERIUM ACNES :

10

EFFICACY OF A NATURAL-BASED BLEACHING CREAM FOR HYPERPIGMENTATION: AN 8-WEEK BLINDED, SPLIT-FACE STUDY VS 4% HYDROQUINONE :

11

EFFICACY OF USTEKINUMAB, A HUMAN INTERLEUKIN-12/23 MONOCLONAL ANTIBODY, IN PSORIATIC ARTHRITIS PATIENTS WITH BASELINE C-REACTIVE PROTEIN ?0.4 VS

12

EVALUATING A ROSACEA TREATMENT SYSTEM CONTAINING A CLEANSER, METRONIDAZOLE, HYDRATING COMPLEXION CORRECTOR, AND SUNSCREEN :

13

FURTHER ENHANCEMENT OF FACIAL APPEARANCE WITH A HYDROQUINONE SKIN CARE SYSTEM PLUS TRETINOIN IN PATIENTS PREVIOUSLY TREATED WITH BOTULINUM TOXIN TYPE A :

14

MAINTENANCE REGIMENS WITH TRIPLE COMBINATION CREAM (0.01% FLUOCINOLONE ACETONIDE+ 4% HYDROQUINONE+ 0.05% TRETINOIN) IN MODERATE TO SEVERE MELASMA :

15

MALIGNANCIES IN USTEKINUMAB-TREATED PSORIASIS PATIENTS: COMPARISONS TO THE GENERAL UNITED STATES POPULATION :

17

SAFETY AND PHARMACOKINETICS OF LIPO-102: A NOVEL INJECTABLE THERAPY FOR THE REDUCTION OF ABDOMINAL SUBCUTANEOUS FAT :

18

THE IMPACT OF NATURAL SUNLIGHT EXPOSURE ON THE SUN PROTECTION FACTOR (SPF) AND UVA PROTECTION OF A SPF-50 SUNSCREEN PRODUCT :

19

LONG-TERM (5 YEAR) POLYMETHYLMETHACRYLATE MICROSPHERE SOFT TISSUE FILLER SAFETY &PATIENT SATISFACTION STUDY:: 18 -MONTH INTERIM ANALYSIS :

20

THE USTEKINUMAB SAFETY EXPERIENCE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS: RESULTS FROM POOLED ANALYSES OF PHASE 2 AND PHASE 3 CLINICAL TRIAL DATA :

21

TREATMENT OF TOPICAL FUNGAL INFECTIONS: A REVIEW OF NAFTIFINE CLINICAL DOUBLE-BLIND STUDIES :

22

TWO DOSES OF SUBCUTANEOUS USTEKINUMAB BASED ON BODY WEIGHT PROVIDES SIMILAR EFFICACY IN HEAVIER AND LIGHTER WEIGHT PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS :